MX2021006618A - Esteroides neuroactivos y sus metodos de uso. - Google Patents

Esteroides neuroactivos y sus metodos de uso.

Info

Publication number
MX2021006618A
MX2021006618A MX2021006618A MX2021006618A MX2021006618A MX 2021006618 A MX2021006618 A MX 2021006618A MX 2021006618 A MX2021006618 A MX 2021006618A MX 2021006618 A MX2021006618 A MX 2021006618A MX 2021006618 A MX2021006618 A MX 2021006618A
Authority
MX
Mexico
Prior art keywords
methods
formula
neuroactive steroids
substituted
compound
Prior art date
Application number
MX2021006618A
Other languages
English (en)
Spanish (es)
Inventor
Francesco G Salituro
Maria Jesus Blanco-Pillado
Marshall Lee Moringstar
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of MX2021006618A publication Critical patent/MX2021006618A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0044—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an estrane or gonane skeleton, including 18-substituted derivatives and derivatives where position 17-beta is substituted by a carbon atom not directly bonded to another carbon atom and not being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2021006618A 2018-12-05 2019-12-05 Esteroides neuroactivos y sus metodos de uso. MX2021006618A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862775470P 2018-12-05 2018-12-05
PCT/US2019/064692 WO2020118060A1 (en) 2018-12-05 2019-12-05 Neuroactive steroids and their methods of use

Publications (1)

Publication Number Publication Date
MX2021006618A true MX2021006618A (es) 2021-09-23

Family

ID=69006056

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2021006618A MX2021006618A (es) 2018-12-05 2019-12-05 Esteroides neuroactivos y sus metodos de uso.
MX2024004788A MX2024004788A (es) 2018-12-05 2021-06-03 Esteroides neuroactivos y sus metodos de uso.
MX2024004789A MX2024004789A (es) 2018-12-05 2021-06-03 Esteroides neuroactivos y sus metodos de uso.
MX2024004790A MX2024004790A (es) 2018-12-05 2021-06-03 Esteroides neuroactivos y sus metodos de uso.

Family Applications After (3)

Application Number Title Priority Date Filing Date
MX2024004788A MX2024004788A (es) 2018-12-05 2021-06-03 Esteroides neuroactivos y sus metodos de uso.
MX2024004789A MX2024004789A (es) 2018-12-05 2021-06-03 Esteroides neuroactivos y sus metodos de uso.
MX2024004790A MX2024004790A (es) 2018-12-05 2021-06-03 Esteroides neuroactivos y sus metodos de uso.

Country Status (14)

Country Link
US (8) US20230322846A9 (cg-RX-API-DMAC7.html)
EP (1) EP3902818A1 (cg-RX-API-DMAC7.html)
JP (3) JP7539378B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250174100A (cg-RX-API-DMAC7.html)
CN (1) CN113383004A (cg-RX-API-DMAC7.html)
AR (1) AR117264A1 (cg-RX-API-DMAC7.html)
AU (3) AU2019392680B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021010996A2 (cg-RX-API-DMAC7.html)
CA (1) CA3120872A1 (cg-RX-API-DMAC7.html)
IL (3) IL312610B2 (cg-RX-API-DMAC7.html)
MA (1) MA54594A (cg-RX-API-DMAC7.html)
MX (4) MX2021006618A (cg-RX-API-DMAC7.html)
TW (3) TWI874337B (cg-RX-API-DMAC7.html)
WO (1) WO2020118060A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201606063RA (en) 2012-01-23 2016-09-29 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
RS62761B1 (sr) 2012-08-21 2022-01-31 Sage Therapeutics Inc Alopregnanolon za lečenje refraktornog epileptičkog statusa
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2018013613A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
US20200291059A1 (en) 2017-12-08 2020-09-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
CA3086299A1 (en) * 2017-12-22 2019-06-27 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
JP7538040B2 (ja) 2018-01-12 2024-08-21 セージ セラピューティクス, インコーポレイテッド CNS障害の処置における使用のためのアザ、オキサ、およびチア-プレグナン-20-オン-3α-オール化合物
TWI848034B (zh) * 2018-12-21 2024-07-11 美商賽吉醫療公司 神經活性類固醇及其組合物
JP7670626B2 (ja) * 2019-05-31 2025-04-30 セージ セラピューティクス, インコーポレイテッド 神経刺激性ステロイド及びその組成物
JP7787635B2 (ja) * 2019-06-27 2025-12-17 セージ セラピューティクス, エルエルシー Cns障害を治療するための組成物及び方法
CA3143545A1 (en) * 2019-06-27 2020-12-30 Sage Therapeutics, Inc. Compounds for treating cns disorders
AU2021238346A1 (en) 2020-03-18 2022-09-29 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
CN112679571A (zh) * 2020-12-24 2021-04-20 广西壮族自治区中国科学院广西植物研究所 一种罗汉果醇衍生物单体、其制备方法及应用
EP4392432A2 (en) * 2021-08-25 2024-07-03 Sage Therapeutics, Inc. Positive nmda-modulating compounds and methods of use thereof
CN115974950A (zh) * 2022-12-23 2023-04-18 上海彩迩文生化科技有限公司 一种3-烷基化的甾体中间体及其制备和应用
CN120936616A (zh) 2023-03-14 2025-11-11 库里亚西班牙公司 用于制备3α-羟基-3β-烷基类固醇的方法和中间体
WO2024197317A2 (en) * 2023-03-23 2024-09-26 Emory University Neurosteroids and prodrugs thereof
CN119529013B (zh) * 2024-11-25 2025-11-07 湖南新合新生物医药有限公司 一种祖拉诺龙中间体的合成方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2969M (fr) * 1963-05-22 1964-11-30 Roussel Uclaf Nouveau médicament notamment pour le traitement des spasmes d'origine coronarienne on viscérale.
ES432106A1 (es) 1973-11-30 1976-11-01 Schering Ag Procedimiento para la preparacion de d-homo-20-cetopregna- nos.
IL48628A0 (en) 1974-12-23 1976-02-29 Schering Ag D-homo-20-keto-pregnanes and process for their manufactur
GB1570394A (en) 1976-01-06 1980-07-02 Glaxo Lab Ltd 11-acyloxy-3-hydroxy steroids
US4060295A (en) 1976-03-15 1977-11-29 Molex Incorporated Zero insertion force printed circuit board edge connector assembly
GB1581234A (en) 1976-04-05 1980-12-10 Glaxo Operations Ltd 11a - amino - 3a - hydroxysteroids
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5939545A (en) 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
BR9509764A (pt) * 1994-11-23 1998-07-07 Cocensys Inc Série androstano e pregnano para modulação alostérica de receptor de gaba
AU3967297A (en) * 1996-08-01 1998-02-25 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
US8569275B2 (en) 2002-08-28 2013-10-29 Harbor Therapeutics, Inc. Steroids having 7-oxgen and 17-heteroaryl substitution
FR2967914A1 (fr) 2010-11-29 2012-06-01 Centre Nat Rech Scient Composes inhibiteurs d'interactions proteine-proteine ciblant les proteines kinases et leurs applications biologiques
EP4717314A2 (en) 2011-10-14 2026-04-01 Sage Therapeutics, LLC 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
US9725481B2 (en) * 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
MY190408A (en) 2014-10-16 2022-04-21 Sage Therapeutics Inc Compositions and methods for treating cns disorders
WO2017049044A1 (en) 2015-09-16 2017-03-23 Bartolucci Giampiero Ursodeoxycholic acid and brain disorders
WO2017187343A2 (en) 2016-04-29 2017-11-02 Thome Kreutz Fernando Nanoemulsions and methods for cancer therapy
WO2018013613A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
CN108727453A (zh) 2017-04-20 2018-11-02 华东理工大学 新型pd-1抑制剂及其应用
EP3728285B1 (en) 2017-12-22 2026-04-08 Sage Therapeutics, LLC Compositions and methods for treating cns disorders
US20200384003A1 (en) 2017-12-29 2020-12-10 Shanghai Lanmu Chemicals Co., Ltd. Triterpenoid-containing pharmaceutical composition and use thereof
US12139508B2 (en) 2018-02-11 2024-11-12 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Steroid derivative regulators, method for preparing the same, and uses thereof
JP2022501348A (ja) 2018-09-19 2022-01-06 モデルナティエックス インコーポレイテッドModernaTX, Inc. ステロール類似体及びその使用
TWI848034B (zh) 2018-12-21 2024-07-11 美商賽吉醫療公司 神經活性類固醇及其組合物
WO2020210117A1 (en) 2019-04-08 2020-10-15 Athenen Therapeutics, Inc. Steroids with altered pharmacokinetic properties and methods of use thereof
WO2020210116A1 (en) 2019-04-08 2020-10-15 Athenen Therapeutics, Inc. Steroids with altered pharmacokinetic properties and methods of use thereof
US20220226350A1 (en) 2019-05-30 2022-07-21 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease
JP7670626B2 (ja) 2019-05-31 2025-04-30 セージ セラピューティクス, インコーポレイテッド 神経刺激性ステロイド及びその組成物
CA3143545A1 (en) 2019-06-27 2020-12-30 Sage Therapeutics, Inc. Compounds for treating cns disorders
US20220396597A1 (en) 2019-10-25 2022-12-15 Washington University Nmdar inhibiting agents and gabaar potentiating agents and uses thereof
CN115768781A (zh) 2020-06-24 2023-03-07 萨奇治疗股份有限公司 3.α.-羟基,17.β.-C(O)-N-芳基取代的神经活性类固醇及其组合物

Also Published As

Publication number Publication date
US11970514B2 (en) 2024-04-30
AU2019392680A1 (en) 2021-06-10
TW202521127A (zh) 2025-06-01
IL312610A (en) 2024-07-01
MX2024004790A (es) 2024-05-09
IL283629A (en) 2021-07-29
AR117264A1 (es) 2021-07-21
IL312611B2 (en) 2025-09-01
US20230322847A1 (en) 2023-10-12
JP2024105504A (ja) 2024-08-06
KR20250174100A (ko) 2025-12-11
BR112021010996A2 (pt) 2021-08-31
JP7539378B2 (ja) 2024-08-23
CA3120872A1 (en) 2020-06-11
US20230322846A9 (en) 2023-10-12
US20240336648A1 (en) 2024-10-10
US20230322848A1 (en) 2023-10-12
TW202039528A (zh) 2020-11-01
JP2025134803A (ja) 2025-09-17
US11999765B2 (en) 2024-06-04
US20230046825A1 (en) 2023-02-16
US20250154194A1 (en) 2025-05-15
MA54594A (fr) 2022-04-06
AU2025203487A1 (en) 2025-05-29
AU2025203485A1 (en) 2025-05-29
US12264177B2 (en) 2025-04-01
US11912738B2 (en) 2024-02-27
TWI874337B (zh) 2025-03-01
IL312611A (en) 2024-07-01
JP7720948B2 (ja) 2025-08-08
US12252509B2 (en) 2025-03-18
CN113383004A (zh) 2021-09-10
US20240343756A1 (en) 2024-10-17
US20240309042A1 (en) 2024-09-19
MX2024004789A (es) 2024-05-09
IL283629B1 (en) 2025-11-01
WO2020118060A1 (en) 2020-06-11
EP3902818A1 (en) 2021-11-03
MX2024004788A (es) 2024-05-09
IL312610B1 (en) 2026-01-01
US12410210B2 (en) 2025-09-09
US20230322849A1 (en) 2023-10-12
KR20210112318A (ko) 2021-09-14
TWI924370B (zh) 2026-05-01
KR102892974B1 (ko) 2025-11-28
IL312611B1 (en) 2025-05-01
IL283629B2 (en) 2026-03-01
IL312610B2 (en) 2026-05-01
AU2019392680B2 (en) 2025-07-10
TW202521129A (zh) 2025-06-01
JP2022510683A (ja) 2022-01-27

Similar Documents

Publication Publication Date Title
MX2024004790A (es) Esteroides neuroactivos y sus metodos de uso.
DOP2023000152A (es) Esteroides neuroactivos y composiciones de estos
MX2021015848A (es) Composiciones y métodos para el tratamiento de trastornos del snc.
UY38296A (es) Derivados de 3–(5–amino–1–oxoisoindolin–2–il)piperidin–2,6–diona y sus usos
JOP20210005A1 (ar) عوامل تحلل مستقبلات الإستروجين الانتقائية
MX2021004159A (es) Esteroides neuroactivos sustituidos en la posicion 10 con un grupo ciclico para uso en el tratamiento de trastornos del snc.
CO2023015419A2 (es) Compuesto de péptido corto de prolina modificado con anillo y uso del mismo
AR105836A1 (es) Compuestos y composiciones útiles para tratar trastornos relacionados con ntrk
CO2020009225A2 (es) Análogos de dihidrobenzofurano e indeno como inhibidores del sarcómero cardíaco
CO2019000932A2 (es) Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica.
MX2024010631A (es) Derivados ciclicos de panteteina y usos de los mismos
AR115949A1 (es) Compuestos heterocíclicos
PE20191235A1 (es) Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente
AR085327A1 (es) Inhibidores del virus de la hepatitis c
MX379474B (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales
AR079026A1 (es) Antagonistas de espiro -oxindol de mdm2
MX2021004452A (es) Esteroides neuroactivos no saturados 9(11) y sus métodos de uso.
UY30107A1 (es) Nuevos derivados de pirimidina, composiciones farmaceuticas conteniendolos, procesos de preparacion y aplicaciones
ECSP15035530A (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas
MX2021011118A (es) Derivados de azolopiridina macrocíclicos como moduladores de eed y prc2.
UY36257A (es) “compuestos de imidazopiridazina”.
MX381182B (es) Compuesto heterociclico biciclico o triciclico novedoso.
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
AR112101A1 (es) Tinostamustina para usar en el tratamiento de la leucemia prolinfocítica de celulas t (t-pll).
MA54713A (fr) Forme posologique parentérale stable d'acétate de cétrorélix